Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO James F. Oliviero III Sells 10,331 Shares

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO James F. Oliviero III sold 10,331 shares of the business’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $3.15, for a total value of $32,542.65. Following the transaction, the chief executive officer now directly owns 3,775,019 shares of the company’s stock, valued at $11,891,309.85. This trade represents a 0.27 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Checkpoint Therapeutics Trading Down 3.1 %

Shares of Checkpoint Therapeutics stock opened at $3.13 on Wednesday. The stock has a fifty day simple moving average of $3.39 and a 200 day simple moving average of $2.99. The company has a market capitalization of $152.84 million, a P/E ratio of -1.70 and a beta of 1.36. Checkpoint Therapeutics, Inc. has a 12-month low of $1.38 and a 12-month high of $4.50.

Checkpoint Therapeutics (NASDAQ:CKPT) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.08). On average, analysts predict that Checkpoint Therapeutics, Inc. will post -0.94 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on CKPT. Lake Street Capital lifted their target price on Checkpoint Therapeutics from $4.00 to $7.00 and gave the company a “buy” rating in a research report on Monday, December 16th. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Checkpoint Therapeutics in a research note on Monday, December 16th. Finally, D. Boral Capital assumed coverage on Checkpoint Therapeutics in a research note on Monday, January 13th. They issued a “buy” rating and a $9.00 price objective on the stock.

Hedge Funds Weigh In On Checkpoint Therapeutics

Hedge funds have recently modified their holdings of the company. Virtu Financial LLC increased its position in shares of Checkpoint Therapeutics by 180.5% during the fourth quarter. Virtu Financial LLC now owns 38,157 shares of the company’s stock valued at $122,000 after acquiring an additional 24,552 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Checkpoint Therapeutics during the 4th quarter valued at $67,000. Charles Schwab Investment Management Inc. purchased a new stake in shares of Checkpoint Therapeutics during the 4th quarter valued at $64,000. SBI Securities Co. Ltd. purchased a new position in shares of Checkpoint Therapeutics in the 4th quarter worth about $32,000. Finally, PUREfi Wealth LLC bought a new position in Checkpoint Therapeutics during the fourth quarter valued at about $32,000. Institutional investors own 22.00% of the company’s stock.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.